Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas Sees Sales Decline through FY2029 on Xtandi LOE, Maps 200 Billion Yen Cuts in 5 Years
Quick Look: Astellas expects falling sales through FY2029 as Xtandi goes off-patent, prompting plans to slash recurring costs by 200 billion yen over five years. The company is betting on five strategic brands — Padcev, Izervay, Vyloy, Veozah, and Xospata…
To read the full story
BUSINESS
- Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
June 17, 2026
- Adstiladrin Expected to Ease Patient Burden in Bladder Cancer: Experts
June 17, 2026
- Astellas CEO’s Pay Rises to 733 Million Yen in FY2025: Securities Report
June 17, 2026
- Torii Starts PIII Trial of Cantharidin for Common Warts
June 17, 2026
- Ono CEO’s Pay Climbs to 260 Million Yen
June 16, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…